Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genentech, Inc.
KaliVir Immunotherapeutics
M.D. Anderson Cancer Center
LG Chem
Maastricht University Medical Center
British Columbia Cancer Agency
University Medical Center Groningen
University of California, San Francisco